Post by KBI Biopharma

How resilient is your biopharma supply chain in the face of shifting geopolitical policies? With the evolving landscape surrounding the BIOSECURE Act and changing tariff frameworks, biopharma innovators are facing a new reality. The industry is being pushed harder than ever to prioritize domestic manufacturing, onshoring, and deep supply chain resilience. While large pharma companies are already investing heavily to eliminate tariff exposures, emerging innovators don't necessarily need to replicate that massive infrastructure. However, you do need a strategic, credible answer when investors or partners ask: "Can this program still move forward if policy changes?" In his latest article for KBI Biopharma, Nicolas Schmitz (Senior Strategic Market Analyst) breaks down exactly what biopharma innovators should be reviewing right now—from cell line development and data storage to choosing the right U.S.-based CDMO partner. As Nicolas notes, speed and cost will always matter, but today, they are no longer enough. The new baseline requires mitigating policy, geographic, and transfer risks. 👉 Read the full insight here to ensure your program is built for this moment: https://hubs.ly/Q04j9Z_l0 #Biopharma #CDMO #BIOSECUREAct #SupplyChain #Biotechnology #Pharmaceuticals #Onshoring #KBIBiopharma